Simultaneous determination of leflunomide and its active metabolite, A77 1726, in human plasma by high-performance liquid chromatography.

The isoxazol derivative leflunomide [N-(4'-trifluoromethylphenyl)-5-methylisoxazole-4-carboxamide] is an inhibitor of de novo pyrimidine synthesis used for the treatment of rheumatoid artrithis. In the present study, a liquid-liquid extraction-based reversed-phase HPLC method with UV detection was validated and applied for the analysis of leflunomide and its active metabolite, A77 1726, in human plasma. The analytes were separated using a mobile phase, consisting of acetonitrile, water and formic acid (40/59.8/0.2, v/v), at a flow rate of 0.5 mL/min, and UV detection at 261 nm. The retention times for A77 1726, leflunomide and warfarin (internal standard) were 8.2, 16.2 and 12.2 min, respectively. The validated quantification range of the method was 0.05-100 micro g/mL for leflunomide and 0.1-100 micro g/mL for A77 1726. The developed procedure was applied to assess steady-state plasma concentrations of A77 1726 in patients with rheumatoid arthritis treated with 10 or 20 mg leflunomide per day.

[1]  R. Schleyerbach,et al.  Leflunomide (HWA 486), a novel immunomodulating compound for the treatment of autoimmune disorders and reactions leading to transplantation rejection , 2005, Agents and Actions.

[2]  Vinod P. Shah,et al.  Bioanalytical Method Validation—A Revisit with a Decade of Progress , 2000, Pharmaceutical Research.

[3]  G. Luxton,et al.  Effect of Hemodialysis on Leflunomide Plasma Concentrations , 2002, The Annals of pharmacotherapy.

[4]  Dayer Jm,et al.  Leflunomide: mode of action in the treatment of rheumatoid arthritis , 2000, Annals of the rheumatic diseases.

[5]  A. Chong,et al.  In vivo mechanism by which leflunomide controls lymphoproliferative and autoimmune disease in MRL/MpJ-lpr/lpr mice. , 1997, Journal of immunology.

[6]  R. Morris,et al.  In vitro and in vivo effects of leflunomide, brequinar, and cyclosporine on pyrimidine biosynthesis. , 1997, Transplantation proceedings.

[7]  Jack Parker Davis,et al.  The immunosuppressive metabolite of leflunomide is a potent inhibitor of human dihydroorotate dehydrogenase. , 1996, Biochemistry.

[8]  H. Cherwinski,et al.  The immunosuppressant leflunomide inhibits lymphocyte proliferation by inhibiting pyrimidine biosynthesis. , 1995, The Journal of pharmacology and experimental therapeutics.

[9]  V. Dias,et al.  Blood Distribution and Single‐Dose Pharmacokinetics of Leflunomide , 1995, Therapeutic drug monitoring.

[10]  L. Lou,et al.  Inhibition of dihydroorotate dehydrogenase by the immunosuppressive agent leflunomide. , 1995, Biochemical pharmacology.

[11]  V. Dias,et al.  Measurement of the Active Leflunomide Metabolite (A77 1726) by Reverse‐Phase High‐Performance Liquid Chromatography , 1995, Therapeutic drug monitoring.

[12]  A. Finnegan,et al.  Inhibition of the epidermal growth factor receptor tyrosine kinase activity by leflunomide , 1993, FEBS letters.

[13]  A. Chong,et al.  LEFLUNOMIDE, A NOVEL IMMUNOSUPPRESSIVE AGENT: THE MECHANISM OF INHIBITION OF T CELL PROLIFERATION , 1993, Transplantation.

[14]  W. Wiegrebe.  Nonsteroidal Anti‐Inflammatory Drugs: Mechanisms and Clinical Use, herausgegeben von A. J. Lewis und D. E. Fürst, 616 Seiten, 150 $, M. Dekker Inc., New York/Basel 1987 , 1988 .